Literature DB >> 10530434

Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria.

S H Zinner1.   

Abstract

Over the past 3 decades, considerable changes have occurred in the types of bacteria causing infection in febrile patients with neutropenia and cancer. Twenty years ago, gram-negative bacteria caused approximately 70% of bloodstream infections. As a probable consequence of long-dwelling intravascular devices, fluoroquinolone prophylaxis, and high-dose chemotherapy-induced mucositis, there has been a shift toward gram-positive coccal bacteremia. In most centers today, approximately 70% of bacteremic isolates are gram-positive cocci. Of potential concern is that antimicrobial-resistant gram-positive organisms are becoming increasingly frequent in patients with neutropenia. Fluoroquinolone-resistant Escherichia coli are being isolated from several cancer centers. Several "new" organisms, such as Stomatococcus mucilaginosus, Bacillus cereus, Leuconostoc species, Corynebacterium jeikeium, Rhodococcus species, Stenotrophomonas maltophilia, Moraxella catarrhalis, Burkholderia cepacia, and Bartonella species, now cause infections in these patients. Careful application of infection-control principles, judicious prophylaxis, appropriate evaluation of new antibiotics, and prompt effective therapy will maximize benefits for these patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10530434     DOI: 10.1086/598620

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  70 in total

Review 1.  Drug-induced myelosuppression : diagnosis and management.

Authors:  Peter J Carey
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Prophylactic application of fluoroquinolones for selective decontamination of the gut: friend or foe.

Authors:  A van Belkum; M C Vos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

3.  Identification of clinical coryneform bacterial isolates: comparison of biochemical methods and sequence analysis of 16S rRNA and rpoB genes.

Authors:  Elisabeth E Adderson; Jan W Boudreaux; Jessica R Cummings; Stanley Pounds; Deborah A Wilson; Gary W Procop; Randall T Hayden
Journal:  J Clin Microbiol       Date:  2007-12-26       Impact factor: 5.948

4.  Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.

Authors:  W V Kern; K Klose; A S Jellen-Ritter; M Oethinger; J Bohnert; P Kern; S Reuter; H von Baum; R Marre
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

5.  Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia.

Authors:  J Montalar; A Segura; C Bosch; A Galan; O Juan; C Molins; V Giner; J Aparicio
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

6.  68-year-old man with neutropenic fever and upper extremity hematoma.

Authors:  Elena Beam; Aaron S Mansfield; Carrie A Thompson
Journal:  Mayo Clin Proc       Date:  2012-12       Impact factor: 7.616

7.  Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999.

Authors:  David M Livermore; Dorothy James; Mark Reacher; Catriona Graham; Thomas Nichols; Peter Stephens; Alan P Johnson; Robert C George
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

8.  Prognostic factors influencing infection-related mortality in patients with acute leukemia in Korea.

Authors:  Jin-Hong Yoo; Su Mi Choi; Dong-Gun Lee; Jung-Hyun Choi; Wan-Shik Shin; Woo-Sung Min; Chun-Choo Kim
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

9.  Infection Probability Score, APACHE II and KARNOFSKY scoring systems as predictors of bloodstream infection onset in hematology-oncology patients.

Authors:  Eleni Apostolopoulou; Vasilios Raftopoulos; Konstantinos Terzis; Ioannis Elefsiniotis
Journal:  BMC Infect Dis       Date:  2010-05-26       Impact factor: 3.090

Review 10.  Rethinking Antimicrobial Prophylaxis in the Transplant Patient in the World of Emerging Resistant Organisms-Where Are We Today?

Authors:  Lucy E Horton; Nina M Haste; Randy A Taplitz
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.